Astec Lifesciences' Q2 FY 2025-26 Quarterly Results
- 30 Oct 2025
Result Summary
- Astec Lifesciences Ltd reported a 18.3% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Sep (Q2 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a decline of 25.6%.
- Its expenses for the quarter were down by 20.3% QoQ and 28.6% YoY.
- The net profit decreased 26.1% QoQ and decreased 36.7% YoY.
- The earnings per share (EPS) of Astec Lifesciences Ltd declined at 11.34 during Q2 FY 2025-26.
Financial Statments for Q2 FY 2025-26
Total Income | 74.84 | 91.59 | 100.54 | -18.3% | -25.6% |
Total Expenses | 99.25 | 124.60 | 139.08 | -20.3% | -28.6% |
Profit Before Tax | -24.41 | -33.02 | -38.54 | -26.1% | -36.7% |
Tax | 0.01 | 0.01 | 0.01 | 0.0% | 0.0% |
Profit After Tax | -24.42 | -33.03 | -38.55 | -26.1% | -36.7% |
Earnings Per Share | -11.34 | -16.85 | -19.66 | -32.7% | -42.3% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Astec Lifesciences Ltd is a company engaged primarily in the manufacture and sale of agrochemical products, focusing on fungicides, insecticides, and herbicides. The company operates within the agricultural sector, providing essential products to support crop protection and yield enhancement. While specific recent developments regarding the company are not available, businesses in this industry are often influenced by factors such as agricultural demand, regulatory changes, and seasonal weather patterns.
Revenue
In the second quarter of the fiscal year 2026 (Q2FY26), Astec Lifesciences Ltd reported a total income of ₹74.84 crores. This represents a decline of 18.3% from the previous quarter, Q1FY26, where the total income was ₹91.59 crores. Year-over-year (YoY), the total income has decreased by 25.6% compared to Q2FY25, where it stood at ₹100.54 crores. This data highlights the changes in revenue performance over the specified periods, with both QoQ and YoY declines evident.
Profitability
Astec Lifesciences Ltd's profitability metrics indicate a negative trend during Q2FY26. The company reported a Profit Before Tax (PBT) of -₹24.41 crores, which is a 26.1% improvement compared to the previous quarter's PBT of -₹33.02 crores. Year-over-year, the PBT has improved by 36.7% from -₹38.54 crores in Q2FY25. The Profit After Tax (PAT) for Q2FY26 was -₹24.42 crores, mirroring the PBT performance in terms of percentage changes for both QoQ and YoY. The Earnings Per Share (EPS) for Q2FY26 was -₹11.34, reflecting a 32.7% QoQ improvement from -₹16.85 in Q1FY26 and a 42.3% YoY improvement from -₹19.66 in Q2FY25.
Operating Metrics
The operating expenses for Astec Lifesciences Ltd in Q2FY26 totaled ₹99.25 crores, marking a 20.3% decrease from the previous quarter's expenses of ₹124.60 crores. Compared to the same quarter last year (Q2FY25), operating expenses have decreased by 28.6% from ₹139.08 crores. Despite the reduction in expenses, the company continues to face challenges in achieving profitability, as reflected in the negative earnings figures. The tax expense remained consistent at ₹0.01 crores across all compared periods, indicating no significant change in tax obligations.